Overview: Biologicals & Immunologicals: Recombinant vaccines: technology and applications
- 1 March 1995
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 5 (3) , 211-217
- https://doi.org/10.1517/13543776.5.3.211
Abstract
Recombinant DNA technology, combined with the current understanding of antigen processing and recognition, provides a wide selection of possible approaches for vaccine development. The selection of a particular vaccine approach can thus be based on the desired outcome. Modern vaccinologists can select from a range of vaccines including subunits, purified proteins or polysaccharides, proteins made by recombinant methods in vitro, live vectors, or polynucleotides. Therefore, the treatment can be tailored according to the immune response desired and the safety, efficacy, and availability of the wild-type organism or naturally produced antigen. This article aims to review several of the recent advances and major patent applications in this area.Keywords
This publication has 39 references indexed in Scilit:
- Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvantVaccine, 1993
- DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibodyHuman Molecular Genetics, 1993
- Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines.The Journal of Experimental Medicine, 1993
- Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral ProteinScience, 1993
- Progress towards the development of new vaccines against whooping coughVaccine, 1992
- Recombinant avirulent Salmonellae as oral vaccine carriersInfection, 1992
- Adenovirus Vectors as Potential Vaccines Against Herpes Simplex VirusClinical Infectious Diseases, 1991
- Protection against malaria by vaccination with sporozoite surface protein 2 plus CS proteinScience, 1991
- Direct Gene Transfer into Mouse Muscle in VivoScience, 1990
- Recognition by major histocompatibility complex class I‐restricted cytolytic T lymphocytes of cells expressing vaccinia‐encoded viral and class I proteinsEuropean Journal of Immunology, 1987